Correlation of Aurora-A expression with the effect of chemoradiation therapy on esophageal squamous cell carcinoma by unknown
Tamotsu et al. BMC Cancer  (2015) 15:323 
DOI 10.1186/s12885-015-1329-3RESEARCH ARTICLE Open AccessCorrelation of Aurora-A expression with the effect
of chemoradiation therapy on esophageal
squamous cell carcinoma
Kiyokazu Tamotsu, Hiroshi Okumura*, Yasuto Uchikado, Yoshiaki Kita, Ken Sasaki, Itaru Omoto, Tetsuhiro Owaki,
Takaaki Arigami, Yoshikazu Uenosono, Akihiro Nakajo, Yuko Kijima, Sumiya Ishigami and Shoji NatsugoeAbstract
Background: Chemoradiation therapy (CRT) is one of the most useful treatments for esophageal squamous cell
carcinoma (ESCC). However, because some patients respond well to CRT and others do not, it is important to be
able to predict response to CRT before beginning treatment by using markers. Aurora-A encodes a cell cycle
regulated serine/threonine kinase that has essential functions in centrosome maturation and chromosome segregation.
In this study, we investigated the relationship between the expression of Aurora-A and the response to CRT in patients
with ESCC.
Methods: We immunohistochemically investigated the expression of Aurora-A in biopsy specimens of untreated
primary tumors of 78 patients with ESCC and determined the relationship between Aurora-A levels and patient
responses to CRT, which consisted of 5-fluorouracil plus cisplatin and 40 Gy of radiation.
Results: Tumors were judged as Aurora-A positive when more than 10% of the cancer cells displayed a distinct positive
nuclear anti-Aurora-A immunoreaction by immunohistochemical evaluation. The tumors of 46 of 78 patients (58.9%)
displayed positive expression of Aurora-A. In terms of clinical response the percentage of patients showing complete
response (CR), incomplete response/stable disease of primary lesion (IR/SD), and progressive disease (PD) was 19.2, 69.2,
and 11.5%, respectively. In terms of histological response the tumor grade of the 41 patients who underwent surgery
was as follows: grade 1, 48.8%; grade 2, 29.2%; grade 3, 22.0%. CRT was effective for patients who had Aurora-A (+)
tumors (clinically: P = 0.0003, histologically: P = 0.036).
Conclusions: Our results suggest that Aurora-A expression in biopsy specimens of primary tumors is associated with
CRT efficacy in patients with ESCC. Assessment of Aurora-A expression in biopsy specimens maybe useful for regarding
the potential utility of CRT therapy for patients with ESCC before treatment.
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Esophageal cancer is one of the most malignant cancers
with an extremely poor prognosis even though various
types of aggressive therapy such as extended lymphade-
nectomy, radiotherapy, chemotherapy and chemoradiation
therapy (CRT) have been used [1-4]. Recent fundamental
research indicated that many biological markers associated
with apoptosis, DNA repair and the cell cycle such as* Correspondence: hokumura@m.kufm.kagoshima-u.ac.jp
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unless otherwise stated.tumor suppressors (p53, p21), cell-cycle regulators (cyclin
D1, CDC25B, 14-3-3 sigma), DNA repair (p53R2, ERCC1)
are associated with response to CRT in esophageal squa-
mous cell carcinoma (ESCC) [5-7]. Most cancers lack
regulation of the cell cycle and cell cycle checkpoints,
resulting in diseases of uncontrolled proliferation [8]. Of
the molecules that are associated with cell cycle check-
points and mitosis, Aurora kinase is a key protein that
plays a role in cell proliferation. Aurora-A has been char-
acterized as a mitotic kinase and encodes a cell cycle regu-
lated serine/threonine kinase that has essential functions
in centrosome maturation and chromosome segregation.al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Table 1 Patient characteristics
Characteristics No.
Gender (male/female) 75/3
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sition of the cell cycle [9]. Recently, overexpression of
Aurora-A was detected in a variety of human cancers such
as carcinomas of the breast, esophagus, pancreas, liver,
bladder and ovary [9-15]. The purpose of this study was to
examine the correlation of Aurora-A expression with the
effect of CRT in ESCC.
Methods
This study was approved by the ethics committee of
Kagoshima University.
Study groups and patient characteristics
The present study group involved 78 consecutive patients
with advanced ESCC who underwent CRT at Kagoshima
University Hospital between 1995 and 2006. Of these
patients, 41 patients underwent CRT followed by eso-
phagectomy with lymph node dissection 4–6 weeks after
completing CRT, and 37 patients received only CRT. In-
formed consent was obtained from all patients and biopsy
specimens of the primary tumors were collected by endo-
scopic examination before CRT. The general condition
and tumor stage of the patients were evaluated before and
after CRT by performance status and by imaging means
such as esophagoscopy, esophagography, computed tom-
ography and endoscopic ultrasonography. Tumor stage
was based on the International Union Against Cancer
tumor-node-metastasis (TNM) classification system [16].
In this period, most of patients were treated with pre-
operative chemotherapy and we adopted CRT to relatively
advanced patients after informed consent. Moreover we
did not adopt CRT to the patients with synchronous or
metachronous cancer in other organs. Therefore the pa-
tient’s number was limited. However, during this period,
the patients were treated by same surgical team under same
treatment strategies.
The study group consisted of 2 patients with stage I,
12 patients with stage II, 30 patients with stage III and
34 patients with stage IV tumors. Thirty-seven patients
were treated with only CRT, including 15 patients with
tumor invasion to adjacent structures by preoperative
diagnosis, 5 patients with refusal of surgery and 17 pa-
tients with poor condition because of their complications.
Thus, 41 patients were judged to be eligible for curative
resection after completing neoadjuvant CRT. The TNM
classification of these 41 patients was as follows; 2, 0, 25
and 14 patients were cT1, T2, T3 and T4 tumors respect-
ively, 13 and 28 cases were cN0 and N1 respectively, 28
and 13 cases were cM0 and M1 respectively and 1, 9, 15
and 16 cases were cStage I, II, III and IV, respectively.
During operation, all cT4 tumors including three pa-
tients with T4 tumors invading to the lung were judged
to be resectable. All of the M1 tumors were due to distant
lymph node metastases. These 41 patients underwentesophagectomy with lymph node dissection and sub-
sequently cervical esophagogastric anastomosis using
a gastric tube was performed. The biopsy specimens
taken were two specimens from carcinoma lesions and
one specimen from normal epithelia. Additional speci-
mens were taken when there were dysplastic lesions. All
patients were followed up after discharge with a radio-
graphic examination every 1–3 months, computed tomog-
raphy every 3–6 months, and ultrasonography every
6 months. Follow-up data after surgery were available for
all patients with a median follow-up period of 24 months
(range 3–136 months). The clinicopathologic features of
the study group are summarized in Table 1.
Chemoradiation therapy
The total radiation dose administered was 40 Gy. 2 Gy
fractions were delivered to the mediastinum and neck
5 days per week for 4 weeks. During the same period,
chemotherapy was administered intravenously using cis-
platin (7 mg/m2) and 5 fluorouracil (350 mg/m2) (4).
For the patients treated without surgery, definitive CRT
(a total radiation dose was more than 50 Gy) was applied.
After 4 weeks, the clinical response to CRT was evaluated
based on the findings of esophagography, esophagoscopy,
endoscopic ultrasonography and computed tomography.
The clinical criteria for response of the primary lesion
were as follows [17]: Complete response (CR); disappear-
ance of endoscopic findings that suggest the presence of a
tumor, no malignant cell by endoscopic biopsy from the
area where the primary tumor had existed, the entire
esophagus can be observed by endoscopy, and no findings
of active esophagitis by endoscopy. Incomplete response/
stable disease of primary lesion (IR/SD); response of the
primary lesion is judged as IR/SD when its response does
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gressive disease. Progressive disease (PD); distinct tumor
growth or progression in esophageal stenosis compared
with the best condition during treatment.
The histological criteria for response to CRT were as
follows [17]. Grade 0; neither necrosis nor cellular or
structural changes can be seen throughout the lesion.
Grade 1; necrosis or disappearance of the tumor is
present in no more than 2/3rds of the whole lesion.
Grade 2; necrosis or disappearance of the tumor is
present in more than 2/3rds of the whole lesion, but vi-
able tumor cells still remain. Grade 3; the whole lesion
displays necrosis and/or is replaced by fibrosis, with or
without granulomatous changes; no viable tumor cells
are observed. A response of Grade 2 or 3 was judged as
effective CRT and a response of Grade 0 or 1 was judged
as ineffective CRT.
Immunohistochemical examination
Aurora-A protein expression was determined using an
immunohistochemical method. Tumor samples were
fixed with 10% formaldehyde in phosphate-buffered
saline (PBS), embedded in paraffin, and section into
4 μm-thick slices. For each tumor sample, three biopsy
specimens, including two cancerous lesions and one nor-
mal epithelium were mounted alongside each other on a
slide glass. Paraffin-embedded sections were dewaxed in
xylene and rehydrated in a graded series of ethanol.
After deparaffinization of the sections, endogenous per-
oxidase was blocked by immersing the slides in a 0.3%
hydrogen peroxidase-methanol solution for 30 minutes
at room temperature. In preparation for staining with
primary antibody, the sections were pretreated with
0.1 M citrate buffer for 10 minutes at 120°C in an auto-
clave. The sections were then incubated with the pri-
mary antibody, anti-Aurora-A antibody (Cell Signaling
Technology#3092) 1:50 diluted with Antibody Diluent
(Dako, Inc) at 4°C overnight [10], followed by staining
using a streptavidin-biotin-peroxidase kit (Nichirei, Tokyo,
Japan). The sections were washed three times with PBS
for 5 min per wash, and the immune complex was visual-
ized by incubating the sections with diaminobenzidine tet-
rahydrochloride. The slides were rinsed briefly in water,
counterstained with haematoxylin and mounted. Esopha-
geal cancer sections that are known to express Aurora-A
were used as positive control slides and a section without
primary antibody was used as a negative control.
The sections were examined under a light microscope.
Evaluation of immunohistochemical data was independ-
ently carried out by two investigators (K.T. and H.O.)
without prior knowledge of patient clinical information.
Positive staining of the nucleus was evaluated in all areas
of the specimen. To establish the cut-off of Aurora-A
expression we have tested the significance value ofcorrelation between CRT response and Aurora-A ex-
pression according to Aurora-A expression rates, such
as 10%, 20%, 30%, 40%, and more than 50%, then best
significance was obtained at 10%. Therefore, tumors were
classified as Aurora-A positive when >10% of the tumor
nuclei were stained.
Statistical analysis
Statistical analysis of group differences was performed
using the χ2 test. A value of P < 0.05 was considered to
be significant. Actuarial survival curves were estimated
using the Kaplan–Meier method, and differences in sur-
vival between subgroups were compared with the log-rank
test and Wilcoxon test. Multivariate analysis was perfor-
med using Cox-hazard model analysis. A p value of < 0.05
was considered to be significant. All p-values are two-
sided in this study. All statistical analyses were performed
using the software package StatView™ version 5.0 (Abacus
Concepts, Berkeley, CA, US).
Results
Expression of Aurora-A in ESCC
Aurora-A expression in ESCC tumor samples was immu-
nohistochemically detected in both the nucleus and the
cytoplasm of the cells. The patterns of expression ob-
served were distinct nuclear expression, or diffuse nuclear
and cytoplasmic expression. Since the dominant cellular
localization of Aurora-A is the centrosome, we counted
tumors with distinct nuclear staining as Aurora-A positive
(Figure 1). Of 78 ECC patients, 58.9% were positive for
Aurora-A expression.
Relationships between Aurora-A expression and response
to CRT
The percentage of patients with a CR, IR/SD or PD clin-
ical response to CRT was: 19.2% (15 out of 78), 69.2%
(54 out of 78) and 11.5% (9 out of 78), respectively. Analysis
of the relationship between the expression of Aurora-A and
the clinical response to CRT indicated that CRT was effect-
ive in patients who had Aurora-A (+) tumors (P = 0.0003)
(Table 2).
The grades of the histological response of the 41 pa-
tients who underwent surgery were as follows: grade 1,
48.8% (20 out of 41 patients); grade 2, 29.2% (12 out of
41 patients) and grade 3, 22.0% (9 out of 41 patients). In
total, the response of 21 patients (51.2%) with grade 2 or
3 was judged as effective CRT, whereas the response of
20 patients (47.2%) with grade 1 was judged as ineffect-
ive CRT. There was a significant correlation between
the pathological and clinical responses to CRT (p = 0.0001).
Analysis of the correlation of Aurora-A expression with
histological effect again indicated that CRT was effective for
patients with Aurora-A (+) tumors (P = 0.003) (Table 3).
A B
Figure 1 Expression of Aurora-A in clinical samples of ESCC tumors. Immunostaining of Aurora-A in representative tumors (original magnification, ×400):
(A) Aurora-A positive ESCC; (B) Aurora-A negative ESCC. Positive distinct Aurora-A staining is detected in the cell nucleus.
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CRT response
The relationship between the expression of Aurora-A
and clinical outcome of the 78 patients was next ana-
lyzed. The 2-year or 5-year survival rates of patients with
Aurora-A (+) and Aurora-A (−) tumors were 49.0 and
28.1% or 29.5 and 28.1%, respectively (P = 0.08, Figure 2A).
Thus the patients with Aurora-A (+) tumors tended to
have a better prognosis than the patients with Aurora-A
(−) tumors. When analyzed according to the clinical re-
sponse to CRT, the 5-year survival rate of patients with
CR and IR/SD, or with PD tumors, were 46.0 and 27.3%,
respectively (P = 0.02, Figure 2B).
Analysis of the clinical outcome according to Aurora-A
levels of the 41 patients who underwent surgery showed
that the 2-year or 5-year survival rates of the patients with
Aurora-A (+) and Aurora-A (−) tumors were 64.8 and
41.2 or 47.1 and 40.2%, respectively (P = 0.3, Figure 2C).
Analysis of the clinical outcome of the same patients
according to the histological response to CRT indicated
that the 5-year survival rate of patients with grade 2 or 3,
or with grade 1 tumors were 61.8 and 21.2%, respectively
(P = 0.002, Figure 2D). Furthermore, for better under-
standing and showing value of Aurora-A, a cox regression
analysis was performed. On univariate regression analyses,
pathological stage (pStage) and histopathological grade
significantly affected postoperative outcome (p = 0.03 andTable 2 Correlation of Aurora-A expression with clinical
response to CRT
Clinical response to CRT (n = 78)
CR IR/SD PD Total P
Aurora-A
(+) 15 29 2 46 0.0003
( − ) 0 25 7 32
CR: Complete Response, complete disappearance of the primary lesion.
IR/SD: Incomplete Response/Stable Disease of the primary lesion.
PD: Progressive Disease, progressive disease of the primary lesion.
Aurora-A (+)/(−), Aurora-A positive/negative expression.0.004, respectively), however nuclear and nuclear + cyto-
plasmic Aurora-A expression did not affect (p = 0.3 and
p = 0.4. respectively). On multivariate analysis, pStage
and histopathological grade were significant prognostic
factors (p = 0.008, hazard ratio = 9.3 and 0.002, hazard
ratio = 5.6 respectively), however nuclear and nuclear +
cytoplasmic Aurora-A expression were not significant
prognostic factors (p = 0.73, hazard ratio = 1.3 and p = 0.91,
hazard ratio = 1.2, respectively) (Table 4).
Discussion
In the present study, we examined the expression of the
Aurora-A protein in ESCC to determine whether such
expression might be useful for predicting the response
to CRT. Of 78 tumors of ESCC patients, 58.9% of the
ESCC tumors were found to have positive expression of
Aurora-A, as assessed by a distinct nuclear anti-Aurora-A
immunoreaction. This percentage is very similar to that
previously reported by Tanaka et al. who reported that
53% of esophageal cancer tissues examined displayed posi-
tive nuclear Aurora-A protein expression [11].
When cells undergo various stresses such as the stresses
following administration of anticancer drugs and radi-
ation, cell cycle checkpoint and cell cycle arrest mecha-
nisms are activated in order to repair damaged DNA and
ensure cell survival. On the other hand, severe DNA
damage induces the apoptosis signaling pathway that
eliminates unrepaired cells by inducing cell death [18].
Cells exposed to ionizing radiation die via different
mechanisms, including apoptosis and mitotic catastro-
phe [19,20]. Mitotic catastrophe occurs when cells with
incompletely replicated genomes or unrepaired DNA
damage enter mitosis. Centrosome amplification is an
important cause of mitotic catastrophe [21,22]. The pre-
sent study showed a significant correlation between
Aurora-A overexpression (Aurora-A (+) cells), which
is correlated to centrosome amplification, and better clin-
ical and histological response to CRT. We consider that
overexpression of Aurora-A enables esophageal cancer
Table 3 Correlation of Aurora-A expression with
histological and clinical responses to CRT in the surgical
group of ESCC patients
Histological response to CRT (n = 41)
Grade1 Grade2 Grade3 Total P
Aurora-A
(+) 7 8 9 24 0.003
( −) 13 4 0 17
Clinical
response
CR 0 1 8 9 0.0001
IR/SD 17 11 1 29
PD 3 0 0 3
Grade 2 or 3 was judged as effective CRT and a response of Grade 1 was
judged as ineffective CRT.
CR: Complete Response, complete disappearance of the primary lesion.
IR/SD: Incomplete Response/Stable Disease of the primary lesion.
PD: Progressive Disease, progressive disease of the primary lesion.
Aurora-A (+)/(−), Aurora-A positive/negative expression.
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ing DNA damage induced by CRT and enter mitosis,
resulting in the occurrence of mitotic catastrophe. There
have been reports that describe a correlation between
better CRT effect and mitotic catastrophe, which causes
dysfunction of G2/M check point regulation, in ESCCA
B
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Figure 2 Disease-specific survival curves of ESCC patients treated with CRT
2-year or 5-year survival rates of patients with Aurora-A (+) and Aurora-A (−) t
(B) Of 78 patients, the 5-year survival rate of patients with CR and IR/SD, or w
(P = 0.02). (C) Of the 41 patients who underwent surgery, the 2-year or 5-year
64.8 and 41.2 or 47.1and 40.2%, respectively (P = 0.3). (D) The 5-year survival r
21.2%, respectively (P = 0.002). P-values were calculated using log-rank tests.patients [7,23]. These results suggest that cell cycle pro-
gression without G2 arrest and DNA repair might cause
mitotic cell death of ESCC that is related to an effective
response to CRT.
In a previous analysis of the correlation of patient sur-
vival with Aurora-A levels, the expression of Aurora-A
was reported to be associated with poor prognosis of
human cancer including esophageal cancer [11]. That
result is in contrast to our study in which patients with
tumors that overexpressed Aurora-A tended to have a
better prognosis in short 2 year period (Figure 2A).
Based on this result, we considered that patients whose
tumors displayed distinct nuclear overexpression of
Aurora-A would have a poor prognosis if they were only
treated with surgery without CRT. The combined data
suggest that there might be a subgroup of ESCC patients
with special characteristics whose malignant potential
would be modified by CRT treatment through overriding
of the G2/M check point followed by mitotic catastro-
phe. In the ESCC patients with treated with CRT, lack of
Aurora-A expression might be a negative prognostic fac-
tor because of poor tumor shrinkage. However when
patients have relapse disease in their follow up periods,
it might be better prognostic factor. Therefore there was
no significant differences on 5 year-survival rates between
patients with Aurora-A (+) and Aurora-A (−) tumors.C
D
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Table 4 Univariate and multivariate analysis of survival in
the surgical group of ESCC patients









I, II (n = 10) 0.03 0.008 9.3 1.8-48.6
III, IV (n = 31) 1
Histopathological
grade
Grade 2, 3 (n = 21) 0.004 0.002 5.6 1.9-16.6
Grade1 (n = 20) 1
Nuclear Aurola-A
(+) (n = 24) 0.30 0.73 1.3 0.3-4.6
(−) (n = 17) 1
Nuclear + cytoplasmic
Aurora-A
(+) (n = 29) 0.40 0.91 1.1 0.2-4.4
(−) (n = 12) 1
Aurora-A (+)/(−), Aurora-A positive/negative expression.
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those phenomena, the present study suggests that favor-
able responses to CRT can be predicted based on distinct
nuclear Aurora-A overexpression in the tumor cells of
ESCC patients.
In conclusion, Aurora-A expression in biopsy specimens
of primary tumors was associated with a favorable re-
sponse to CRT of ESCC patients. Assessment of Aurora-A
expression in tumor biopsy specimens before therapy, will
allow selection of patient response to CRT.
Conclusions
We demonstrated that CRT was significantly effective in
patients who had Aurora-A (+) tumors not only clinically
but also histologically. Moreover the patients with Aurora-
A (+) tumors tended to have a better prognosis than the
patients with Aurora-A (−) tumors. Thus assessment of
Aurora-A expression in tumor biopsy specimens before
therapy will be useful for selection responders of CRT.
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